COVID-19 Response: Local Logistics     National Effort       

Double Mutant Coagulation Factor VIII and Methods Therof

You are here

COVID-19 Response: Local Logistics     National Effort

The Novel Technology: 

 
The technology relates to the production of more active and stable recombinant B-domain deleted (BDD) Factor VIII protein. Specifically, double mutant BDD Factor VIII with combined mutations of Phe309Ser and Asp519Val has been generated. 
 
Applications:
  • To use in the field of haemophilia therapeutics 
  • To improve efficacy of recombinant Factor VIII molecule
  • To get good specific activity for present needs comparable to existing products
Advantages:
  • No foreign sequences included and hence lower risk
  • Double mutant recombinant Factor VIII results in higher secretion, enhanced activity and stability compared to the wild type BDD Factor VIII
  • Fewer steps and more efficient steps ensuring good recovery of intact Factor VIII without pre-activation
Business Model: 
 
This invention is in early stage of development. Looking for potential licensee(s) interested in taking the technology to next step of development. There is a high possibility of approaching funding agencies for any financial need for furthering the development.
 
Principal Investigator(s): Prof. M. A. Vijiyalakhsmi, CBST
 
Invention ID: CMP-026
 
IP status: Patent Pending
 
Jurisdictions: India (IN), PCT filed 
 
For more details, please write to:
techtransfer @ ccamp.res.in